Study on Effectiveness of Adding Phenobarbitone to Conventional Therapy in Preterm Neonates with Unconjugated Hyperbiliurubinemia in Comparison with Conventional Therapy

Saipriya, M; Vidhyadhari, D; Gowtham, G; Pelluri, Ranakishore; Yashodhara, P.; Nadendla, Ramarao

doi:10.9734/bjpr/2016/22174

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence prophylactic phenobarbital seems to be a cheap alternative. 23 Phenobarbital also proved efficacy on decreasing serum bilirubin level in term neonates in different dosage form and route of administrations, Hamidi M et al ,2013 5 mg/kg phenobarbital was used orally. 4 while in Suh HJ, et al Korean study (1996 )3 mg/kg phenobarbital was used as intramuscular injection.…”

Section: Resultsmentioning

confidence: 99%

The Role of Oral Phenobarbital Therapy in the Management of Neonates with Prolonged Unconjugated Hyperbilirubinemia

Mahdi Al-Musawi,

N. Al-Musawi,

Muayad Mohammed Ali

2019

Qad Med J

View full text Add to dashboard Cite

Background: Prolonged jaundice is a type of neonatal jaundice, which occurs in infants with high bilirubin levels (>10 mg/dl) persisting beyond day 14 of life in term neonates, and beyond day 21 in preterm neonates. Prolonged jaundice may be caused by predominantly conjugated or unconjugated hyperbilirubinemia. Distinguishing between these types of jaundice helps to determine the risk for pathological causes of prolonged jaundice. Phenobarbital has been used to treat neonatal jaundice since the 1960s. Numerous clinical trials have shown that both administration of phenobarbital to pregnant mothers before delivery and phenobarbital administration to neonates after delivery limit the severity of unconjugated hyperbilirubinemia, reduce the peak serum total bilirubin concentrations caused by physiologic jaundice by 50%, and the need for exchange transfusion. Objective: The aim of this study was to evaluate the role of phenobarbital in reducing the total serum bilirubin(TSB) in neonates with prolonged unconjugated hyperbilirubinemia. Methods: This is a prospective clinical trial study that was performed in Karbala teaching hospital for children from 18th of December 2017 to the end of December 2018. A total of 101 neonate with prolonged unconjugated hyperbilirubinemia were included in this study. All neonates who included in this study received phenobarbital tablet (5 mg /kg/day) twice a day for 10 days and some of them need phototherapy according to American Academy Of Pediatrics Guidelines for phototherapy, Results: There was a highly statistically significant decrease in TSB for the patients who were treated with phenobarbital compared to the baseline level, mean baseline TSB 14.57± 2.31 mg/dl versus TSB after phenobarbital 6.79±1.62 mg/dl (P value <0.001). There was a highly statistically significant decrease in TSB for the patients who were treated with phototherapy in addition to phenobarbital compared to the baseline level, mean baseline TSB 19.94±1.36 mg/dl versus TSB after phototherapy and phenobarbital 6.33±1.37 mg/dl (P value <0.001). Conclusions: Oral phenobarbital supplementation in the neonates with prolonged unconjugated hyperbilirubinemia can significantly accelerate reduction in serum bilirubin levels. Phenobarbital was safe, tolerable and no obvious adverse effects had been reported. No need for cessation of breast feeding in cases of presumed breast milk jaundice.

show abstract

Section: Resultsmentioning

confidence: 99%

The Role of Oral Phenobarbital Therapy in the Management of Neonates with Prolonged Unconjugated Hyperbilirubinemia

Mahdi Al-Musawi,

N. Al-Musawi,

Muayad Mohammed Ali

2019

Qad Med J

View full text Add to dashboard Cite

show abstract

“…Kaabneh et al concluded that the oral dose of 2.5 mg/kg phenobarbital in combination with phototherapy might help newborns with isoimmune hemolytic diseases and lead to a faster decrease in TSB (84). Another study revealed that oral prophylactic and therapeutic usage of phenobarbital (3 mg/kg/day at 6 hours of life and the next 5 days) significantly reduces the peak serum bilirubin level and decreases the duration of phototherapy in very low birth weight infants (83,85). Phenobarbital supplementation in neonates with prolonged IHB can significantly accelerate the reduction in the serum bilirubin level (82).…”

Section: Phenobarbitalmentioning

confidence: 99%

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Nouri

Zarkesh

2023

J Compr Ped

View full text Add to dashboard Cite

Context: Hyperbilirubinemia is a common cause for diagnostic work-up and therapeutic intervention in neonates and needs a convenient, quick, and safe treatment modality. Phototherapy is the most common treatment for neonatal jaundice; however, complementary treatment is still needed. Despite the identification of the enzymatic pathways of bilirubin catabolism, few pharmacological interventions have been found to be effective in reducing bilirubin, along with traditional phototherapy. This review was conducted to evaluate recent pharmacotherapies as adjuvants to phototherapy for the treatment of neonatal indirect hyperbilirubinemia (IHB). Evidence Acquisition: This study was carried out through a literature search with the keywords of Infant, Newborn, and Indirect Hyperbilirubinemia, combined with Drug Therapy, in PubMed, Scopus, International Statistical Institute, Web of Science, Cochrane, and Embase databases. This study included relevant articles (i.e., randomized controlled trials, observational studies, guidelines, and reviews) written in English and published between 2012 - 2022. Results: This narrative review first assessed the relevant articles to define IHB and its etiology. Then, the efficacy and side effects of recent pharmacologic agents as adjuvants to phototherapy were discussed. Additionally, this study reviewed the efficacy and safety of drugs prescribed to neonates to prevent jaundice. Conclusions: The best drug for adjuvant pharmacotherapy, in addition to phototherapy, for neonatal jaundice has not still been identified. The use of probiotics, prebiotics, synbiotics, and ursodeoxycholic acid (UDCA) in adjuvant to phototherapy has been recently increasing, and beneficial results were observed in most studies. The use of agar, charcoal, fibrate, and phenobarbital had a minor therapeutic role in recent years. There were conflicting results about the efficacy of herbal agents in neonatal jaundice. The use of intravenous immunoglobulin (IVIG), metalloporphyrin, and albumin is also limited to severe or immune-related IHB cases. The prescription of the aforementioned drugs sometimes had different results. Therefore, further research in this regard is necessary.

show abstract

Study on Effectiveness of Adding Phenobarbitone to Conventional Therapy in Preterm Neonates with Unconjugated Hyperbiliurubinemia in Comparison with Conventional Therapy

Cited by 2 publications

References 0 publications

The Role of Oral Phenobarbital Therapy in the Management of Neonates with Prolonged Unconjugated Hyperbilirubinemia

The Role of Oral Phenobarbital Therapy in the Management of Neonates with Prolonged Unconjugated Hyperbilirubinemia

Recent Advances in Adjuvant Pharmacotherapy for Neonatal Indirect Hyperbilirubinemia: A Narrative Review

Contact Info

Product

Resources

About